ARBISER JACK L has a total of 24 patent applications. Its first patent ever was published in 2003. It filed its patents most often in United States, EPO (European Patent Office) and China. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are EUTHYMICS BIOSCIENCE INC, COLUCID PHARMACEUTICALS INC and SIGNUM BIOSCIENCES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | EPO (European Patent Office) | 7 | |
#3 | China | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Canada | 1 | |
#6 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Arbiser Jack L | 22 |
#2 | Bai Xianhe | 1 |
#3 | Whitmore David | 1 |
#4 | Amblard Frank | 1 |
#5 | Frank Amblard | 1 |
#6 | Amblard Franck | 1 |
#7 | Furness Scott M | 1 |
#8 | Watkins E Blake | 1 |
#9 | Arbiser Jack | 1 |
#10 | Bowen J Philip | 1 |
Publication | Filing date | Title |
---|---|---|
US2014335079A1 | Solenopsin and derivatives, therapeutic compositions, and methods related thereto | |
US2012196870A1 | Combination therapy | |
US2012165406A1 | Bis-trifluoromethyl honokiol analogs and their use in treating cancers | |
CN101742991A | Honokiol analogs and their use in treating cancers | |
EP2099305A1 | Novel palladium complexes inhibit n-myristoyltransferase activity in vitro and cancer growth in vivo | |
US2008108707A1 | Antiangiogenic, antitumor, chemopreventative agents | |
CN101223120A | Honokiol derivatives for the treatment of proliferative disorders | |
WO03061598A2 | Solenopsin a, b and analogs as novel angiogenesis inhibitors |